The key developments include the following: (i) Midostaurin, an FLT3 inhibitor, marked the start of the new era [8], followed by gilteritinib for FLT3-ITD mutations [9]; (ii) Ivosidenib and enasidenib target IDH mutations, which is observed in 5–15% of AML cases [10]; (iii) Venetoclax, a BCL-2 inhibitor, is approved for elderly patients over 75 years, in combination with standard treatments [11]; (iv) Gemtuzumab ozogamicin, targeting CD33, is approved for relapsed or refractory AML [12]. This evidence concerns the gene FLT3 and acute myeloid leukemia.